Blog
How the FDA can score quick wins on transparency
The agency needs to organize its shambolic online collection of public documents.
A new take on developing drugs for chronic pain
Despite a recent failure, Lilly’s master protocol trial shows a path forward in chronic pain R&D.
How to learn about biotech and pharma
Want to get up to speed on the biopharma biz? We’ve got you covered.
Red flags in biotech press releases
Learn the classic signs of spin and misdirection in biotech PR about clinical trial results.
How risky is that biotech trial?
A framework to more methodically assess clinical development probability of success (POS).
Introductory resources for analyzing biotech clinical trial results
Learn to analyze biotech trials like a pro!
Does Boston have too many clinical trials?
Our data shed light on disparities in clinical study access across U.S. urban areas.
A biotech VC’s prescription for what ails pharma
How can we balance innovation and affordability in prescription drugs? Peter Kolchinsky has some ideas.
How smart pharma can stop making bad R&D choices
R&D portfolio strategy is so … unstrategic. Together with Navigant’s Greg Belogolovsky, we have some ideas to fix it.
When biotechs get breakthrough therapy status, Mr. Market yawns
As Jay-Z might say, breakthrough status may provide 99 benefits, but excess stock returns ain’t one.